“Oncometabolism: The switchboard of cancer: An editorial”

Otto Warburg, biochemist, FDA, FDG-PET, MRS, Oncometabolism

Otto Warburg's discovery in the 1920s highlighted a unique bioenergetic phenotype in tumor cells, emphasizing their reliance on lactic acid fermentation, which spurred the field of oncometabolism. Oncometabolism has led to advancements like FDG-PET imaging for cancer diagnosis and staging,…

Feb 1^st • 1 min read

Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

FDA, hepatic dysfunction, child-pugh, national cancer institute, dosing, oncology compounds

The FDA and European Medicines Agency recommend using Child-Pugh classification for pharmacokinetic evaluation in noncancer subjects with hepatic impairment (HI). Dosing recommendations for oncology compounds for patients with HI are commonly based on Child-Pugh classification. In oncology …

Jul 20^th • 18 mins read